Skip main navigation

New offer! Get 30% off one whole year of Unlimited learning. Subscribe for just £249.99 £174.99. New subscribers only T&Cs apply

Find out more

Formulating Biologics

Dear fellow student, this is Dr. Lee again. And we’re going to work on part three of the biotechnology mini-series. The title for this talk is formulation of biotechnology products. And the materials are taken from these 2 references. Learning objectives, we’re going to discuss the formulation approaches to improve the bioavailability of biotechnology products. To explain the effect of glycosylation and pegylation on the pharmacokinetics of biotechnology products And to explain the targeted delivery of biotechnology product and the therapeutic benefit. And we are going to discuss the additives that are used in the parenteral formulation of biotechnology products And to describe the microbiological considerations of quality control or biotechnology products. And lastly to describe the ascetic conditions for the manufacturing of biotechnology products.
First of all, let’s look at all possible route of drug administration. Parenteral route include IV, SC, IM, IP and others such as intrathecal. Non parenteral route includes PO that is oral. Nasal, transdermal, and others such as intraocular. And given the choice PO or the oral nutrition will be the most desirable route. However, following oral administration of biologics, you’re not going to fare very well. Because oral administration results in very low oral bioavailability for the following reasons. First, proteins degrade by peptidase and a protease in the GI tract. Secondly, large molecules have poor permeability of the GI membranes, and the diffusion coefficient decreases with increasing molecular size.
Now here oral vaccine is probably the only exceptional because the target cells are lymphocyte and only a small fraction of the dose is needed to reach the target site for immune response such as polio vaccine. Now parenteral administration when given intravenously it doesn’t fare very well either because IV injection is subject to immunogenic response and then the drug is rapidly cleared. IM is not as rapidly cleared as IV, but it is subjective metabolic degradation at the site of injection. And that leaves SC the ideal route.
In addition, receptor binding is a part of elimination process. It’s not merely to elicit from a logical response as in the case of small molecules So overall, parental administration exhibits poor uptake and quick circulatory turnover.

Welcome to week 4. This week, we will learn formulation of biotechnology products. First, I am going to give a brief overview and guide to formulation and process development as well as manufacturing of biologic products. Some fundamental and specific considerations are presented.

This section summarizes factors that involve in the formulation of biologics, including route of administration, dosage forms, manufacturing conditions and quality control considerations In addition, bioavailability and targeted delivery are examined Structural modification, such as pegylation and glycosylation are considered from a formulation perspective

Please leave any questions or thoughts pertaining to this topic below.

This article is from the free online

Pharmacotherapy: Understanding Biotechnology Products

Created by
FutureLearn - Learning For Life

Reach your personal and professional goals

Unlock access to hundreds of expert online courses and degrees from top universities and educators to gain accredited qualifications and professional CV-building certificates.

Join over 18 million learners to launch, switch or build upon your career, all at your own pace, across a wide range of topic areas.

Start Learning now